|Bid||5.67 x 1000|
|Ask||5.68 x 1100|
|Day's Range||5.66 - 5.93|
|52 Week Range||5.30 - 18.55|
|Beta (5Y Monthly)||1.73|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 26, 2024 - Mar 01, 2024|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||19.60|
Subscribe to Yahoo Finance Plus to view Fair Value for NVAX
Novavax stock is on the rise after the World Health Organization signed off on its Covid shot. Is NVAX stock a buy or a sell right now?
Novavax's updated vaccine has been granted emergency-use authorization by the World Health Organization (WHO) for active immunization to prevent COVID-19 in individuals aged 12 and older, the company said on Tuesday. The updated Novavax shot, which was authorized in the U.S. last month, targets a descendant of the XBB lineage of the coronavirus that was globally predominant earlier this year. The emergency use listing helps speed up the regulatory approvals to import and administer the vaccines by member states, according to the WHO.
Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Nuvaxovid™ XBB.1.5 COVID-19 Vaccine (NVX-CoV2601) has been granted Emergency Use Listing (EUL) by the World Health Organization (WHO) for active immunization to prevent COVID-19 in individuals aged 12 and older. The EUL assists WHO member states in assessing vaccines with the aim of expediting availability and enables the WHO's 194 member states to expedite regulatory